David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study (French Language Version)

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).

Leukemia

Margaret O'Donnell, MD

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).

Multiple Myeloma

Sagar Lonial, MD, and Torben Plesner, MD

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (Abstract 507).

Lymphoma

Nathan Hale Fowler, MD

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 470).

Aug

Today In Oncology

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study (French Language Version)

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk

Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses

FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices

Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma